Research Output per year
Fingerprint Dive into the research topics where Samantha Bowyer is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
Melanoma
Medicine & Life Sciences
Antibodies
Medicine & Life Sciences
Therapeutics
Medicine & Life Sciences
Pneumonia
Medicine & Life Sciences
Phase III Clinical Trials
Medicine & Life Sciences
ipilimumab
Medicine & Life Sciences
Treatment Failure
Medicine & Life Sciences
Diarrhea
Medicine & Life Sciences
Network
Recent external collaboration on country level. Dive into details by clicking on the dots.
Research Output 2016 2018
Dabrafenib and trametinib treatment-associated fevers in metastatic melanoma causing extreme elevation in procalcitonin in the absence of infection
Clay, T. D. & Bowyer, S. E., Sep 2018, In : Anti-Cancer Drugs. 29, 8, p. 802-805 4 p.Research output: Contribution to journal › Article
Reply to 'Comment on 'Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy''
Bowyer, S., Prithviraj, P., Lorigan, P., Larkin, J., McArthur, G., Atkinson, V., Millward, M., Khou, M., Diem, S., Ramanujam, S., Kong, B., Liniker, E., Guminski, A., Parente, P., Andrews, M. C., Parakh, S., Cebon, J., Long, G. V., Carlino, M. S. & Klein, O., 11 Apr 2017, In : British Journal of Cancer. 116, 8, p. e15Research output: Contribution to journal › Letter
Open Access
Efficacy and toxicity of treatment with the anti-CTLA-4 antibody ipilimumab in patients with metastatic melanoma after prior anti-PD-1 therapy
Bowyer, S., Prithviraj, P., Lorigan, P., Larkin, J., Mcarthur, G., Atkinson, V., Millward, M., Khou, M., Diem, S., Ramanujam, S., Kong, B., Liniker, E., Guminski, A., Parente, P., Andrews, M. C., Parakh, S., Cebon, J., Long, G. V., Carlino, M. S. & Klein, O., 2016, In : British Journal of Cancer. 114, 10, p. 1084-1089Research output: Contribution to journal › Article
Open Access
Melanoma
Antibodies
Therapeutics
Pneumonia
Phase III Clinical Trials